Angiodynamics Free Cash Flow (FCF) History (ANGO)
Angiodynamics reported $508,000 in free cash flow for fiscal 2026, an increase of $15.1M from the previous fiscal year, with a free cash flow margin of 0.16%.
View full Angiodynamics company overviewAngiodynamics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-05-31 | $508,000 | $15.1M | — | +0.16% |
| 2025 | 2025-05-31 | −$14.6M | $16.1M | — | −4.99% |
| 2024 | 2024-05-31 | −$30.7M | −$26.9M | — | −10.09% |
| 2023 | 2023-05-31 | −$3.7M | $7.8M | — | −1.10% |
| 2022 | 2022-05-31 | −$11.5M | −$30.4M | — | −3.63% |
| 2021 | 2021-05-31 | $18.9M | $40.7M | — | +6.50% |
| 2020 | 2020-05-31 | −$21.8M | −$56.1M | — | −8.25% |
| 2019 | 2019-05-31 | $34.3M | −$4.6M | −11.76% | +12.68% |
| 2018 | 2018-05-31 | $38.9M | −$13.8M | −26.26% | +14.87% |
| 2017 | 2017-05-31 | $52.7M | $9.9M | +22.98% | +19.55% |
| 2016 | 2016-05-31 | $42.9M | $28.6M | +199.89% | +12.12% |
| 2015 | 2015-05-31 | $14.3M | $793,000 | +5.87% | +4.01% |
| 2014 | 2014-05-31 | $13.5M | −$1.0M | −7.04% | +3.81% |
| 2013 | 2013-05-31 | $14.5M | $5.4M | +59.52% | +4.25% |
| 2012 | 2012-05-31 | $9.1M | −$21.8M | −70.53% | +4.11% |
| 2011 | 2011-05-31 | $30.9M | −$4.0M | −11.47% | +14.34% |
| 2010 | 2010-05-31 | $34.9M | — | — | +16.16% |
Angiodynamics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2026 | 2026-05-31 | $17.0M | −$995,000 | −5.52% | +19.67% |
| Q3 2026 | 2026-02-28 | −$4.1M | $10.8M | — | −5.26% |
| Q2 2026 | 2025-11-30 | $4.2M | $2.6M | +152.92% | +5.34% |
| Q1 2026 | 2025-08-31 | −$16.6M | $2.7M | — | −21.98% |
| Q4 2025 | 2025-05-31 | $18.0M | $13.6M | +306.63% | +22.50% |
| Q3 2025 | 2025-02-28 | −$15.0M | −$1.8M | — | −20.77% |
| Q2 2025 | 2024-11-30 | $1.7M | −$3.0M | −64.43% | +2.30% |
| Q1 2025 | 2024-08-31 | −$19.3M | $7.3M | — | −28.66% |
| Q4 2024 | 2024-05-31 | $4.4M | −$10.5M | −70.23% | +6.25% |
| Q3 2024 | 2024-02-29 | −$13.1M | −$13.8M | — | −17.47% |
| Q2 2024 | 2023-11-30 | $4.7M | −$1.5M | −24.22% | +5.96% |
| Q1 2024 | 2023-08-31 | −$26.7M | −$1.1M | — | −33.92% |
| Q4 2023 | 2023-05-31 | $14.9M | $7.4M | +98.09% | +16.36% |
| Q3 2023 | 2023-02-28 | $704,000 | $10.6M | — | +0.87% |
| Q2 2023 | 2022-11-30 | $6.2M | $5.4M | +667.65% | +7.28% |
| Q1 2023 | 2022-08-31 | −$25.6M | −$15.6M | — | −31.34% |
| Q4 2022 | 2022-05-31 | $7.5M | −$4.1M | −35.05% | +8.65% |
| Q3 2022 | 2022-02-28 | −$9.9M | −$14.4M | — | −13.38% |
| Q2 2022 | 2021-11-30 | $810,000 | −$9.3M | −91.97% | +1.03% |
| Q1 2022 | 2021-08-31 | −$9.9M | −$2.7M | — | −12.89% |
| Q4 2021 | 2021-05-31 | $11.6M | $9.2M | +382.26% | +15.07% |
| Q3 2021 | 2021-02-28 | $4.5M | $24.1M | — | +6.31% |
| Q2 2021 | 2020-11-30 | $10.1M | $6.8M | +204.38% | +13.86% |
| Q1 2021 | 2020-08-31 | −$7.2M | $676,000 | — | −10.32% |
| Q4 2020 | 2020-05-31 | $2.4M | −$21.8M | −90.08% | +4.12% |
| Q3 2020 | 2020-02-29 | −$19.6M | −$27.0M | — | −28.06% |
| Q2 2020 | 2019-11-30 | $3.3M | −$8.9M | −72.89% | +4.73% |
| Q1 2020 | 2019-08-31 | −$7.9M | $1.6M | — | −12.00% |
| Q4 2019 | 2019-05-31 | $24.2M | $1.2M | +5.08% | +33.99% |
| Q3 2019 | 2019-02-28 | $7.5M | $3.6M | +91.65% | +11.38% |
| Q2 2019 | 2018-11-30 | $12.2M | $2.8M | +29.45% | +17.47% |
| Q1 2019 | 2018-08-31 | −$9.6M | −$12.1M | — | −14.94% |
| Q4 2018 | 2018-05-31 | $23.0M | $4.8M | +26.18% | +404.91% |
| Q3 2018 | 2018-02-28 | $3.9M | −$10.1M | −72.12% | +4.64% |
| Q2 2018 | 2017-11-30 | $9.4M | −$4.1M | −30.47% | +10.89% |
| Q1 2018 | 2017-08-31 | $2.5M | −$4.4M | −63.57% | +2.97% |
| Q4 2017 | 2017-05-31 | $18.3M | $137,000 | +0.76% | +258.54% |
| Q3 2017 | 2017-02-28 | $14.0M | $2.3M | +19.59% | +16.30% |
| Q2 2017 | 2016-11-30 | $13.6M | $4.4M | +48.37% | +15.26% |
| Q1 2017 | 2016-08-31 | $7.0M | $3.0M | +75.91% | +7.90% |
| Q4 2016 | 2016-05-31 | $18.1M | $8.2M | +82.89% | +19.39% |
| Q3 2016 | 2016-02-29 | $11.7M | $3.0M | +33.86% | +13.34% |
| Q2 2016 | 2015-11-30 | $9.2M | $13.7M | — | +10.25% |
| Q1 2016 | 2015-08-31 | $4.0M | $3.7M | +1495.16% | +4.72% |
| Q4 2015 | 2015-05-31 | $9.9M | $2.6M | +34.97% | +10.95% |
| Q3 2015 | 2015-02-28 | $8.7M | $11.1M | — | +10.07% |
| Q2 2015 | 2014-11-30 | −$4.6M | −$8.7M | — | −4.96% |
| Q1 2015 | 2014-08-31 | $248,000 | −$4.1M | −94.36% | +0.28% |
| Q4 2014 | 2014-05-31 | $7.3M | $613,000 | +9.12% | +7.80% |
| Q3 2014 | 2014-02-28 | −$2.4M | −$9.5M | — | −2.72% |
| Q2 2014 | 2013-11-30 | $4.2M | −$3.1M | −42.95% | +4.71% |
| Q1 2014 | 2013-08-31 | $4.4M | $11.0M | — | +5.26% |
| Q4 2013 | 2013-05-31 | $6.7M | $8.2M | — | +7.50% |
| Q3 2013 | 2013-02-28 | $7.1M | $1.1M | +18.62% | +8.68% |
| Q2 2013 | 2012-11-30 | $7.3M | $5.2M | +239.68% | +8.40% |
| Q1 2013 | 2012-08-31 | −$6.6M | −$9.1M | — | −7.87% |
| Q4 2012 | 2012-05-31 | −$1.5M | −$12.4M | — | −2.62% |
| Q3 2012 | 2012-02-29 | $6.0M | −$3.9M | −39.50% | +11.57% |
| Q2 2012 | 2011-11-30 | $2.2M | −$6.9M | −76.25% | +3.70% |
| Q1 2012 | 2011-08-31 | $2.5M | $1.4M | +132.62% | +4.60% |
| Q4 2011 | 2011-05-31 | $10.9M | — | — | +19.45% |
| Q3 2011 | 2011-02-28 | $9.9M | — | — | +18.05% |
| Q2 2011 | 2010-11-30 | $9.1M | — | — | +16.98% |
| Q1 2011 | 2010-08-31 | $1.1M | — | — | +2.09% |
Angiodynamics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $18.9M to $508,000, a compound annual decline of 51.49%. Angiodynamics's latest reported quarter, Q4 2026, generated $17.0M in free cash flow, a decrease of 5.52% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Angiodynamics filings at SEC.gov ↗